Psychodynamic Psychopharmacology
American Psychiatric Association Publishing (Verlag)
978-1-61537-152-5 (ISBN)
The first part of the book explores the evidence base that guides how, rather than simply what, to prescribe. It describes precisely what psychodynamic psychopharmacology is and why its emphasis on combining the often-neglected psychosocial aspects of medication with biomedical considerations provides a more optimized approach to addressing treatment resistance.
Part II delves into the psychodynamics that contribute to pharmacological treatment resistance, both when patients' ambivalence about their illness, the medication itself, or their prescriber manifests in nonadherence and when medications support a negative identity or are used as replacements for healthy capacities. Readers will gain basic skills for addressing the psychological and interpersonal dynamics that underpin both scenarios and will be better positioned to ameliorate interferences with the healthy use of medications.
The final section of the book offers detailed technical recommendations for addressing pharmacological treatment resistance. It tackles issues that include countertransference-driven irrational prescribing; primitive dynamics, such as splitting and projective identification; and the overlap between psychopharmacological treatment resistance and the dynamics of treatment nonadherence and nonresponse in integrated and collaborative medical care settings.
By putting the individual patient back at the center of the therapeutic equation, psychodynamic psychopharmacology, as outlined in this book, offers a model that moves beyond compliance and emphasizes instead the alliance between patient and prescriber. In doing so, it empowers patients to become more active contributors in their own recovery.
David Mintz, M.D., is Director of Psychiatric Education, Associate Director of Training, and a Team Leader at the Austen Riggs Center in Stockbridge, Massachusetts.rect
Preface
Part 1: What is Psychodynamic Psychopharmacology
Chapter 1: Introduction – What is Psychodynamic Psychopharmacology
Chapter 2: Why Psychodynamic Psychopharmacology?
Chapter 3: What is Psychodynamic about Psychodynamic Psychopharmacology?
Part 2: Understanding Pharmacologic Treatment Resistance
Chapter 4: The Psychodynamics of Pharmacologic Treatment Resistance
Chapter 5: Treatment Resistance to Medications
Chapter 6: Treatment Resistance from Medications
Chapter 7: The Prescriber's Contribution to Treatment Resistance
Part 3: The Manual of Psychodynamic Psychopharmacology
Chapter 8: Avoid a mind-body split
Chapter 9: Know who the patient is
Chapter 10: Attend to the patient's ambivalence
Chapter 11: Cultivate the pharmacotherapeutic alliance
Chapter 12: Address countertherapeutic uses of medications
Chapter 13: Identify and contain countertransference prescribing
Chapter 14: What patient populations are appropriate for psychodynamic psychopharmacology?
Chapter 15: Before initiating treatment
Chapter 16: The Engagement phase
Chapter 17: Maintenance Phase
Chapter 18: Split and Combined Treatments
Chapter 19: Integrated Care
Appendix 1: Self-Assessment Checklist
Appendix 2: Glossary
Index
| Erscheinungsdatum | 05.07.2021 |
|---|---|
| Zusatzinfo | 5 figures, 31 tables |
| Verlagsort | VA |
| Sprache | englisch |
| Maße | 151 x 228 mm |
| Gewicht | 408 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie |
| ISBN-10 | 1-61537-152-4 / 1615371524 |
| ISBN-13 | 978-1-61537-152-5 / 9781615371525 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
